Kan 25-hidroksi D vitamini düzeyinin fibrokistik meme hastalığı ve meme yoğunluğu ile ilişkisi

Amaç: Bu çalışmanın amacı kan 25-hidroksi D vitamin seviyesinin memenin fibrokistik kitleleri ve meme paternleri ile olan ilişkisini değerlendirmektir. Gereç ve Yöntem: Çalışmaya 2018-2021 yılları arasında meme şikayeti veya rutin tarama için başvuran, meme ultrasonografi (USG) ve mamografi (MG) tetkiki istenen 612 hasta dahil edildi. Memede fibrokistik kitlesi olanlar (BI-RADS 2-3) grup 1 ve memede kitlesi olmayanlar (BI-RADS 1) grup 2 olmak üzere hastalar iki gruba ayrıldı. Her iki grup; yaş, meme USG, MG sonuçları ve kan 25-hidroksi D vitamin seviyeleri açısından karşılaştırıldı. Bulgular: Çalışmaya dahil edilen kadınların 310 (%51)’da memede fibrokistik kitle tespit edilirken, 302 (%49)’sinin memesi normaldi. Her iki grubun yaş ortalaması benzerdi. Memede fibrokistik kitlesi olanların kontrol grubuna göre D vitamin seviyesi daha düşük ve meme yoğunluğunun daha fazla olduğu tespit edildi. Meme yoğunluğu fazla olan grubun az olan gruba göre D vitamini seviyesinin daha düşük olduğu ve D vitamin seviyesi ile meme yoğunluğu arasında negatif korelasyon olduğu bulundu. Sonuç: Çalışmamızda memesinde fibrokistik kitlesi (BI-RADS2 ve BI-RADS3) olan kadınlarda, memesinde kitle olmayan kadınlara göre meme yoğunluğunun daha fazla ve D vitamini seviyesinin daha düşük olduğu bulundu.

Anahtar Kelimeler:

Memenin fibrokistik kitlesi, meme yoğunluğu, D vitamini

Relationship of blood 25-hydroxy vitamin D level with fibrocystic breast disease and breast density

Purpose: The aim of this study is to evaluate the association of blood 25-hydroxy vitamin D levels with fibrocystic breast masses and breast patterns. Materials and Methods: The study included 612 patients who presented with breast complaints or referred for routine screening between 2018-2021 and were requested to have breast ultrasonography (USG) and mammography (MG) examinations. Patients were divided into two groups; group 1 consisted of women with fibrocystic mass (BI-RADS 2-3) and group 2 consisted of women without breast mass (BI-RADS 1). These two groups were compared by age, breast USG, MG results, and blood 25-hydroxy vitamin D levels. Results: Of the 612 patients, 310 (51%) had fibrocystic mass in their breasts, while 302 (49%) had normal breasts. The mean age of both groups was similar. Those with fibrocystic mass in the breast had lower vitamin D levels and higher breast density than the control group. The group with higher breast density had lower vitamin D levels, and there was a negative correlation between vitamin D level and breast density Conclusion: Our study revealed that women with fibrocystic masses in their breasts (BI- RADS2 and BI-RADS3) had higher breast density and lower vitamin D levels than women without breast mass.

Keywords:

Fibrocystic Breast Masses, Breast Density, Vitamin D,

PDF

___

1. Guray M, Sahin AA. Benign breast diseases: classification, diagnosis and management. Oncologist. 2006;11:435–49.
2. Talaei A, Moradi A, Rafiei F. The evaluation of the effect of metformin on breast fibrocystic disease. Breast Dis. 2017;37:49-53.
3. Gopalani S V, Janitz AE, Martinez SA, Gutman P, Khan S, Campbell JE. Trends in cancer incidence among American indians and Alaska natives and nonhispanic whites in the United States, 1999-2015. Epidemiology. 2020;31:205–13.
4. Ameen F, Reda SA, El-Shatoury SA, Riad EM, Enany ME, Alarfaj AA. Prevalence of antibiotic resistant mastitis pathogens in dairy cows in Egypt and potential biological control agents produced from plant endophytic actinobacteria. Saudi J Biol Sci. 2019;26:1492–8.
5. Lundberg FE, Iliadou AN, Rodriguez-Wallberg K, Gemzell-Danielsson K, Johansson ALV. The risk of breast and gynecological cancer in women with a diagnosis of infertility: A nationwide populationbased study. Eur J Epidemiol. 2019;34:499–507.
6. Li YR, Tang YX, Qiu CX, Lin QY, Xie CJ, Zhou MY et al. Analysis of common gynecological diseases in 1142 married female workers. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2019;37:785–8.
7. Autenshlyus AI, Studenikina AA, Bernado AV, Mikhailova ES, Proskura AV, Sidorov SV et al. Assessment of the cytokine-producing resource of tumor biopsy samples from patients with invasive carcinoma of no special type and with non-malignant breast diseases. Biomed Khim. 2019;65:418–23.
8. Luo WQ, Huang QX, Huang XW, Hu HT, Zeng FQ, Wang W. Predicting breast cancer in Breast Imaging Reporting and Data System (BI-RADS) Ultrasound category 4 or 5 lesions: a nomogram combining radiomics and BI-RADS. Sci Rep. 2019;9:11921.
9. Zhang F, Jin L, Jia C, Shi Q. The role of contrastenhanced ultrasound in the diagnosis of malignant non-mass breast lesions and exploration of diagnostic criteria. Br J Radiol. 2021;94:1120.
10. Alikhassi A, Esmaili Gourabi H, Baikpour M. Comparison of inter- and intra-observer variability of breast density assessments using the fourth and fifth editions of Breast Imaging Reporting and Data System. Eur J Radiol Open. 2018;5:67-72.
11. Lee CI, Chen LE, Elmore JG. Risk-based breast cancer screening: implications of breast density. Med Clin North Am. 2017;101:725-41.
12. Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol. 2005;6:798–808.
13. Holick MF. Medical progress: Vitamin D deficiency. N Engl J Med. 2007;357:266–81.
14. Gabaj NN, Unic A, Miler M, Pavicic T, Culej J, Bolanca I et al. In sickness and in health: Pivotal role of vitamin D. Biochem Med . 2020;30:1–13.
15. Cranney A, Horsley T, O’Donnell S, Weiler H, Puil L, Ooi D et al. Effectiveness and safety of vitamin D in relation to bone health. Evid Rep Technol Assess. 2007;1.
16. Boeke CE, Tamimi RM, Berkey CS, Colditz GA, Giovannucci E, Malspeis S et al. Adolescent dietary vitamin D and sun exposure in relation to benign breast disease. Cancer Causes Control. 2015;26:1181– 7.
17. Garland CF, Gorham ED, Mohr SB, Grant, WB, Giovannucci E L, Lipkin M et al. Vitamin D and prevention of breast cancer: Pooled analysis. J Steroid Biochem Mol Biol. 2007;103:708-11.
18. Lopes N, Paredes J, Costa JL, Ylstra B, Schmitt F. Vitamin D and the mammary gland: A review on its role in normal development and breast cancer. Breast Cancer Res. 2012;14.
19. Erdfelder E, FAul F, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behav Res Methods. 2009;41:1149–60.
20. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175–91.
21. Nielsen M, Christensen L, Andersen J. Contralateral cancerous breast lesions in women with clinical invasive breast carcinoma. Cancer. 1986;57:897–903.
22. Sappino AP, Skalli O, Jackson B, Schürch W, Gabbiani G. Smooth‐muscle differentiation in stromal cells of malignant and non‐malignant breast tissues. Int J Cancer. 1988;41:707–12.
23. de La Puente-Yagüe M, Cuadrado-Cenzual MA, Ciudad-Cabañas MJ, Hernández-Cabria M, ColladoYurrita L. Vitamin D: and its role in breast cancer . Kaohsiung J Med Sci. 2018;34:423–7.
24. Welsh JE. Vitamin D and breast cancer: Past and present. J Steroid Biochem Mol Biol. 2018;177:15–20.
25. Khatun A, Fujimoto M, Kito H, Niwa S, Suzuki T, Ohya S. Down-regulation of Ca2+-activated K+ channel KCa1.1 in human breast cancer MDA-MB453 cells treated with vitamin D receptor agonists. Int J Mol Sci. 2016;17.
26. Simboli-Campbell M, Narvaez CJ, Tenniswood M, Welsh JE. 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 1996;58:367–76.
27. Høyer-Hansen M, Bastholm L, Mathiasen IS, Elling F, Jäättelä M. Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death. Cell Death Differ. 2005;12:1297–309.
28. Manson JE, Mayne ST, Clinton SK. Vitamin D and prevention of cancer ready for prime time? N Engl J Med. 2011;364:1385–7.
29. Krishnan A V, Feldman D. Mechanisms of the anticancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol. 2011;51:311–36.
30. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009;94:26–34.
31. Flanagan L, Packman K, Juba B, O'Neill S, Tenniswood M, Welsh J. Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. J Steroid Biochem Mol Biol. 2003;84:181-92.
32. Jiang X, Dimou NL, Al-Dabhani K, Lewis SJ, Martin RM, Haycock PC et al. Circulating Vitamin D concentrations and risk of breast and prostate cancer: A Mendelian randomization study. Int J Epidemiol. 2019;48:1416–24.
33. Voutsadakis IA. Vitamin D baseline levels at diagnosis of breast cancer: A systematic review and metaanalysis. Hematol Oncol Stem Cell Ther. 2021;14:16– 26.
34. Nazari SS, Mukherjee P. An overview of mammographic density and its association with breast cancer. Breast Cancer. 2018;25:259–67.
35. Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol. 2005;6:798–808.
36. Brisson J, Diorio C, Mâsse B. Wolfe's parenchymal pattern and percentage of the breast with mammographic densities: redundant or complementary classifications?. Cancer Epidemiol Biomarkers Prev. 2003;12:728-32.
37. Hunter A. Mammographic density: The risk and detection of breast caner. Journal of Biolaw and Business. 2007;10:60–1.
38. Fletcher SW , Elmore JG . Mammography screening for breast cancer. Med Lett Drugs Ther. 1980;22:53– 4.
39. Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MRE et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med. 2002;347:886–94.
40. Boyd NF, Martin LJ, Bronskill M, Yaffe MJ, Duric N, Minkin S. Breast tissue composition and susceptibility to breast cancer. J Natl Cancer Inst. 2010;102:1224– 37.
41. Bell RJ. Mammographic density and breast cancer screening. Climacteric. 2020;23:460–5.
42. Wood ME, Liu H, Storrick E, Zahrieh D, Le-Petross HC, Jung SH et al. The influence of vitamin D on mammographic density: Results from CALGB 70806 a randomized clinical trial. Cancer Prev Res. 2021;14:753–62.
43. Brisson J, Bérubé S, Diorio C, Mâsse B, Lemieux J, Duchesne T et al. A randomized double-blind placebo-controlled trial of the effect of Vitamin D3 supplementation on breast density in premenopausal women. Cancer Epidemiol Biomarkers Prev. 2017;26:1233–41.
44. Duma N, Croghan I, Jenkins S, Vachon C, Neal L, Ghosh K et al. Assessing Vitamin D and mammographic breast density in Alaskan women. Clin Pract. 2020;10:89–92